Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma (Q37500336)

20 August 2017

1 reference

title

Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma (English)

1 reference

20 August 2017

1 reference

Anil Kapoor

1

1 reference

PubMed ID

19479976

20 August 2017

Robert A Figlin

series ordinal

2

1 reference

PubMed ID

19479976

20 August 2017

language of work or name

English

0 references

publication date

1 August 2009

1 reference

20 August 2017

1 reference

20 August 2017

115

1 reference

20 August 2017

3618-3630

1 reference

20 August 2017

16

1 reference

Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1

20 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Defining the role of mTOR in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

PI 3-kinase, mTOR, protein synthesis and cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Growing roles for the mTOR pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

A mammalian protein targeted by G1-arresting rapamycin-receptor complex

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Activation of the mTOR signaling pathway in renal clear cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Role of VHL gene mutation in human cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Targeting von Hippel-Lindau pathway in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Loss of tumor suppressor protein PTEN during renal carcinogenesis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Intragenic PTEN/MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

The TOR pathway: a target for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Predicted mechanisms of resistance to mTOR inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

The FRB domain of mTOR: NMR solution structure and inhibitor design

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Phase I/II Trial of Temsirolimus Combined With Interferon Alfa for Advanced Renal Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Opposite translational control of GLUT1 and GLUT4 glucose transporter mRNAs in response to insulin. Role of mammalian target of rapamycin, protein kinase b, and phosphatidylinositol 3-kinase in GLUT1 mRNA translation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: A crossroad between cancer and diabetes?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24409

7 January 2021

Identifiers

DOI

10.1002/CNCR.24409

1 reference

20 August 2017

1 reference

PubMed ID

19479976